Education
About Us
Working with TipRanks
Follow Us
HABA Laboratories, Inc. (JP:4925)
:4925
RESEARCH TOOLSreports
Top Page
HABA Laboratories, Inc.
(4925)
Rating:61Neutral
Price Target:
¥1,815.00
▲(5.40%Upside)
HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.51B
Dividend Yield2.33%
Average Volume (3M)810.00
Price to Earnings (P/E)11.3
Beta (1Y)0.27
Revenue Growth-2.13%
EPS GrowthN/A
CountryJP
Employees631
SectorConsumer Defensive
Sector Strength62
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)94.05
Shares Outstanding3,935,000
10 Day Avg. Volume790
30 Day Avg. Volume810
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.83
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HABA Laboratories, Inc. Business Overview & Revenue Model
Company DescriptionHABA Laboratories, Inc. (4925) is a Japan-based company that operates in the personal care sector. The company focuses on the development, manufacturing, and marketing of health and beauty-related products. Its core products include skincare items, cosmetics, and health supplements, which are designed to cater to a wide range of consumer needs, emphasizing the use of natural and safe ingredients.
How the Company Makes MoneyHABA Laboratories, Inc. generates revenue primarily through the sale of its skincare, cosmetics, and health supplement products. The company's revenue model is based on direct sales through its retail outlets, online platforms, and distribution through various retail partners. Significant revenue streams include both domestic and international sales, leveraging brand recognition and quality to appeal to a broad customer base. Additionally, HABA Laboratories may engage in strategic partnerships with other companies in the beauty and health industries, further boosting its market presence and contributing to its earnings.
HABA Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 12.30B | 12.32B | 12.04B | 12.91B | 14.31B | 18.37B | Gross Profit |
| 8.32B | 8.03B | 8.17B | 8.79B | 10.20B | 13.66B | EBIT |
| 606.55M | -187.77M | -609.64M | -316.73M | 226.97M | 2.00B | EBITDA |
| -537.20M | -1.31B | 17.05M | 448.30M | 960.14M | 2.56B | Net Income Common Stockholders |
| -986.62M | -2.12B | -707.87M | -269.03M | 216.42M | 1.31B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.01B | 3.96B | 4.82B | 5.65B | 5.66B | 5.23B | Total Assets |
| 12.20B | 12.43B | 14.66B | 15.69B | 17.44B | 17.09B | Total Debt |
| 2.11B | 2.36B | 2.03B | 2.56B | 3.92B | 2.94B | Net Debt |
| -1.90B | -1.60B | -2.78B | -3.09B | -1.74B | -2.29B | Total Liabilities |
| 3.62B | 3.92B | 3.88B | 4.05B | 5.40B | 5.12B | Stockholders Equity |
| 8.57B | 8.51B | 10.77B | 11.64B | 12.04B | 11.97B |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | -1.02B | -232.69M | 1.53B | -346.95M | -234.47M | Operating Cash Flow |
| 0.00 | -587.92M | 55.96M | 1.71B | 534.71M | 675.51M | Investing Cash Flow |
| 0.00 | -441.79M | -214.40M | -216.49M | -925.08M | -920.26M | Financing Cash Flow |
| 0.00 | 171.06M | -676.32M | -1.51B | 825.38M | -448.74M |
HABA Laboratories, Inc. Technical Analysis
Neutral
1722.00
Price Trends
1711.98
Positive
1709.75
Positive
1761.25
Negative
Market Momentum
-2.02
Positive
48.85
Neutral
34.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Neutral. The current price of 1722 is below the 20-day moving average (MA) of 1726.05, above the 50-day MA of 1711.98, and below the 200-day MA of 1761.25, indicating a neutral trend. The MACD of -2.02 indicates Positive momentum. The RSI at 48.85 is Neutral, neither overbought nor oversold. The STOCH value of 34.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4925.
HABA Laboratories, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥10.27B | 28.83 | 3.55% | 11.96% | -70.25% | ||
70 Outperform | ¥11.09B | 15.58 | 6.02% | 12.45% | -3.67% | ||
65 Neutral | $8.88B | 15.03 | 4.75% | 203.74% | 3.58% | -2.49% | |
61 Neutral | ¥6.51B | 11.29 | 2.33% | -2.13% | ― | ||
58 Neutral | ¥8.24B | 10.52 | ― | -19.98% | ― | ||
55 Neutral | ¥6.06B | 148.30 | 1.59% | -7.66% | ― | ||
45 Neutral | ¥4.81B | 35.28 | 1.78% | 0.10% | -239.09% |
* Consumer Defensive Sector Average
Performance Comparison
JP:4925
HABA Laboratories, Inc.
1,722.00
-278.90
-13.94%
JP:4926
C'BON COSMETICS Co., Ltd.
1,121.00
-253.68
-18.45%
JP:4929
ADJUVANT HOLDINGS CO., LTD.
752.00
-109.38
-12.70%
JP:4932
Almado, Inc.
1,097.00
-102.71
-8.56%
JP:4934
Premier Anti-Aging Co., Ltd.
960.00
128.00
15.38%
JP:4936
AXXZIA, Inc.
429.00
-500.18
-53.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.